Cargando…

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety

BACKGROUND: Marzeptacog alfa (activated) (MarzAA), a novel recombinant activated human factor VII (FVIIa) variant, was developed to provide increased procoagulant activity, subcutaneous (SC) administration, and longer duration of action in people with hemophilia. OBJECTIVES: To investigate if daily...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahlangu, Johnny, Levy, Howard, Kosinova, Marina V., Khachatryan, Heghine, Korczowski, Bartosz, Makhaldiani, Levani, Iosava, Genadi, Lee, Martin, Del Greco, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371347/ https://www.ncbi.nlm.nih.gov/pubmed/34430790 http://dx.doi.org/10.1002/rth2.12576

Ejemplares similares

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
por: Lentz, S R, et al.
Publicado: (2014)

Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
por: Faraj, Alan, et al.
Publicado: (2023)

Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
por: Faraj, Alan, et al.
Publicado: (2022)

Recombinant single‐chain factor VIII in severe hemophilia: Long‐term safety and efficacy in previously treated patients in the AFFINITY extension study
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Limited factor VIIa surface localization requirement of the factor VIIa–induced overall thrombin generation in platelet‐rich hemophilia A plasma
por: Persson, Egon, et al.
Publicado: (2019)

Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study)
por: Djambas Khayat, Claudia, et al.
Publicado: (2021)

A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
por: Lentz, Steven R, et al.
Publicado: (2014)

A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand
por: Mehta, Darshan A., et al.
Publicado: (2016)

Violin concertos in C major, Hob. VIIa:1 ; in G major, Hob. VIIa:4 ; in A major, Hob. VIIa:3 /
por: Haydn, Joseph, 1732-1809
Publicado: (1989)

Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
por: Korczowski, Bartosz, et al.
Publicado: (2023)

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A
por: Korth‐Bradley, Joan, et al.
Publicado: (2018)

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A
por: George, Lindsey A, et al.
Publicado: (2015)

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
por: Napolitano, Mariasanta, et al.
Publicado: (2019)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa
por: Butros, Linda, et al.
Publicado: (2011)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon(®) and Eprex(®) following a single subcutaneous administration in healthy male volunteers
por: Yoon, Sumin, et al.
Publicado: (2017)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
por: Kempton, Christine, et al.
Publicado: (2021)

Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
por: Takedani, Hideyuki, et al.
Publicado: (2015)

Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A
por: Hyun, Shin Young, et al.
Publicado: (2015)

Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review
por: Sella, Carola, et al.
Publicado: (2023)

HCV Genotypes of People with Hemophilia in Countries with High Seroprevalances
por: Mahlangu, J N, et al.
Publicado: (2011)

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
por: Zollner, S, et al.
Publicado: (2014)

A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH
por: van Galen, Karin P. M., et al.
Publicado: (2021)

Hemophilia gene therapy knowledge and perceptions: Results of an international survey
por: Peyvandi, Flora, et al.
Publicado: (2020)

Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses
por: Demartis, Francesco, et al.
Publicado: (2017)

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)
por: Auerswald, Guenter, et al.
Publicado: (2020)

Apixaban and eftrenonacog alfa treatment in a patient with moderate hemophilia B and cardiovascular disease
por: Santoro, Rita C., et al.
Publicado: (2021)

Factor VIIa for severe cardiac surgical bleeding
por: Diprose, P, et al.
Publicado: (2002)

Preclinical trauma studies of recombinant factor VIIa
por: Schreiber, Martin A, et al.
Publicado: (2005)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
por: Fishbane, Steven, et al.
Publicado: (2019)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
por: Kenet, Gili, et al.
Publicado: (2023)

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
por: John, M. Joseph, et al.
Publicado: (2020)

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
por: Lissitchkov, Toshko, et al.
Publicado: (2022)

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management
por: Benitez Hidalgo, Olga, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s12sqejet063a07g0uiv3v1dc5